{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:52:09Z","timestamp":1773687129327,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"UKRI MRC","award":["MR\/N00065X\/1"],"award-info":[{"award-number":["MR\/N00065X\/1"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018336","name":"Health Protection Research Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.<\/jats:p>","DOI":"10.1093\/jac\/dkad314","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:11:48Z","timestamp":1700777508000},"page":"ii37-ii42","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-1490","authenticated-orcid":false,"given":"Sabine","family":"Bou-Antoun","sequence":"first","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakib","family":"Rokadiya","sequence":"additional","affiliation":[{"name":"Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-2028","authenticated-orcid":false,"given":"Diane","family":"Ashiru-Oredope","sequence":"additional","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Demirjian","sequence":"additional","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"},{"name":"Department of Paediatric Infectious Diseases & Immunology, Evelina London Children's Hospital , London , UK"},{"name":"Faculty of Life Sciences & Medicine, King\u2019s College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Sherwood","sequence":"additional","affiliation":[{"name":"Clinical and Emerging Infections (CEI), United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Ellaby","sequence":"additional","affiliation":[{"name":"Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gerver","sequence":"additional","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlota","family":"Grossi","sequence":"additional","affiliation":[{"name":"COVID-19 Rapid Evidence Service Public Health Advice, Guidance and Expertise (PHAGE), UK Health Security Agency , London NW9 5EQ , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Harman","sequence":"additional","affiliation":[{"name":"COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency , London NW9 5EQ , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Hartman","sequence":"additional","affiliation":[{"name":"Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-1293","authenticated-orcid":false,"given":"Alessandra","family":"Lochen","sequence":"additional","affiliation":[{"name":"Tuberculosis (TB), Acute Respiratory, Zoonoses, Emerging and Travel infections Division, UK Health Security Agency , London NW9 5EQ , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Ragonnet-Cronin","sequence":"additional","affiliation":[{"name":"Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA) , London , UK"},{"name":"MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , UK"},{"name":"Department of Ecology and Evolution, University of Chicago , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Squire","sequence":"additional","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Mark","family":"Sutton","sequence":"additional","affiliation":[{"name":"Research and Evaluation, UK Health Security Agency, Porton Down , Salisbury SP4 0JG , UK"},{"name":"Institute of Pharmaceutical Sciences, King\u2019s College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Thelwall","sequence":"additional","affiliation":[{"name":"COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency , London NW9 5EQ , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Tree","sequence":"additional","affiliation":[{"name":"Research and Evaluation, UK Health Security Agency, Porton Down , Salisbury SP4 0JG , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad W","family":"Bahar","sequence":"additional","affiliation":[{"name":"Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics , Oxford , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I","family":"Stuart","sequence":"additional","affiliation":[{"name":"Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics , Oxford , UK"},{"name":"Diamond Light Source Ltd, Harwell Science & Innovation Campus , Didcot , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin S","family":"Brown","sequence":"additional","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Chand","sequence":"additional","affiliation":[{"name":"Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2023112322105313600_dkad314-B1","author":"O'Neill"},{"key":"2023112322105313600_dkad314-B2","doi-asserted-by":"crossref","first-page":"dlac016","DOI":"10.1093\/jacamr\/dlac016","article-title":"Antibiotic resistance: calling time on the \u2018silent pandemic\u2019","volume":"4","author":"Mendelson","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023112322105313600_dkad314-B3","author":"Horby","year":"2021"},{"key":"2023112322105313600_dkad314-B4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med"},{"key":"2023112322105313600_dkad314-B5","author":"Medicines and Healthcare Products Regulatory Agency (MHRA)"},{"key":"2023112322105313600_dkad314-B6","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMc2202861","article-title":"SARS-CoV-2 evolution and immune escape in immunocompromised patients","volume":"386","author":"Scherer","year":"2022","journal-title":"N Engl J Med"},{"key":"2023112322105313600_dkad314-B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/165.1.105","article-title":"Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects","volume":"165","author":"Boucher","year":"1992","journal-title":"J Infect Dis"},{"key":"2023112322105313600_dkad314-B8","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1073\/pnas.89.5.1934","article-title":"Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine","volume":"89","author":"Kellam","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112322105313600_dkad314-B9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.2479983","article-title":"Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)","volume":"246","author":"Larder","year":"1989","journal-title":"Science"},{"key":"2023112322105313600_dkad314-B10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"2023112322105313600_dkad314-B11","first-page":"27","article-title":"Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors","volume":"9","author":"Roberts","year":"1995","journal-title":"AIDS"},{"key":"2023112322105313600_dkad314-B12","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023112322105313600_dkad314-B13","first-page":"2022.02.15.480166","article-title":"Neutralization of SARS-CoV-2 omicron BA.2 by therapeutic monoclonal antibodies","author":"Zhou","year":"2022","journal-title":"bioRxiv"},{"key":"2023112322105313600_dkad314-B14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"2023112322105313600_dkad314-B15","doi-asserted-by":"crossref","first-page":"o61","DOI":"10.1136\/bmj.o61","article-title":"COVID-19: we have good treatments for omicron, but questions remain, say doctors","volume":"376","author":"Wilkinson","year":"2022","journal-title":"BMJ"},{"key":"2023112322105313600_dkad314-B16","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023112322105313600_dkad314-B17","author":"(UKHSA); UHSA"},{"key":"2023112322105313600_dkad314-B18","author":"UK Health Security Agency (UKHSA) and NHS England"},{"key":"2023112322105313600_dkad314-B19","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"key":"2023112322105313600_dkad314-B20","author":"UK Health Security Agency"},{"key":"2023112322105313600_dkad314-B21","doi-asserted-by":"crossref","first-page":"e0251170","DOI":"10.1371\/journal.pone.0251170","article-title":"Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis","volume":"16","author":"Musuuza","year":"2021","journal-title":"PLoS One"},{"key":"2023112322105313600_dkad314-B22","doi-asserted-by":"crossref","first-page":"e24151","DOI":"10.1002\/jcla.24151","article-title":"Worldwide prevalence of microbial agents\u2019 coinfection among COVID-19 patients: a comprehensive updated systematic review and meta-analysis","volume":"36","author":"Pakzad","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"2023112322105313600_dkad314-B23","first-page":"2459","article-title":"Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing","volume":"71","author":"Rawson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023112322105313600_dkad314-B24","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.mayocp.2020.07.001","article-title":"Leveraging existing strategies of medication stewardship to preserve and appropriately use critical supplies","volume":"95","author":"Tande","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2023112322105313600_dkad314-B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13756-021-01010-w","article-title":"Assessing the impact of the global point prevalence survey of antimicrobial consumption and resistance (Global-PPS) on hospital antimicrobial stewardship programmes: results of a worldwide survey","volume":"10","author":"Pauwels","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023112322105313600_dkad314-B26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/antibiotics10020110","article-title":"Assessing the impact of COVID-19 on antimicrobial stewardship activities\/programs in the United Kingdom","volume":"10","author":"Ashiru-Oredope","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023112322105313600_dkad314-B27","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jac5.1329","article-title":"Global contributions of pharmacists during the COVID-19 pandemic","volume":"3","author":"Goff","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"key":"2023112322105313600_dkad314-B28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jac5.1622","article-title":"Global resilience and new strategies needed for antimicrobial stewardship during the COVID-19 pandemic and beyond","volume":"5","author":"Goff","year":"2022","journal-title":"J Am Coll Clin Pharm"},{"key":"2023112322105313600_dkad314-B29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ajhp\/zxaa419","article-title":"Antimicrobial stewardship perspectives from a New York city hospital during the COVID-19 pandemic: challenges and opportunities","volume":"78","author":"Kubin","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"2023112322105313600_dkad314-B30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11908-020-00734-x","article-title":"Antimicrobial stewardship at the core of COVID-19 response efforts: implications for sustaining and building programs","volume":"22","author":"Mazdeyasna","year":"2020","journal-title":"Curr Infect Dis Rep"},{"key":"2023112322105313600_dkad314-B31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijid.2021.10.001","article-title":"COVID-19 and antimicrobial stewardship: lessons learned, best practices, and future implications","volume":"113","author":"Pierce","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023112322105313600_dkad314-B32"},{"key":"2023112322105313600_dkad314-B33","first-page":"e000276","article-title":"Trends, variation and clinical characteristics of recipients of antivirals and neutralising monoclonal antibodies for non-hospitalised COVID-19: a descriptive cohort study of 23.4 million people in OpenSAFELY","volume":"2","author":"Green","year":"2023","journal-title":"medRxiv"},{"key":"2023112322105313600_dkad314-B34"},{"key":"2023112322105313600_dkad314-B35"},{"key":"2023112322105313600_dkad314-B36","author":"Medicines and Healthcare Products Regulatory Agency (MHRA)"},{"key":"2023112322105313600_dkad314-B37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"2023112322105313600_dkad314-B38","doi-asserted-by":"crossref","first-page":"e048502","DOI":"10.1136\/bmjopen-2020-048502","article-title":"Adverse effects of remdesivir, hydroxychloroquine and lopinavir\/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials","volume":"12","author":"Izcovich","year":"2022","journal-title":"BMJ Open"},{"key":"2023112322105313600_dkad314-B39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s15010-022-01825-8","article-title":"Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis","volume":"51","author":"Deng","year":"2022","journal-title":"Infection"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/Supplement_2\/ii37\/53710268\/dkad314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/Supplement_2\/ii37\/53710268\/dkad314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:12:06Z","timestamp":1700777526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/Supplement_2\/ii37\/7444805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2023,11,23]]},"published-print":{"date-parts":[[2023,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad314","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11]]}}}